Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04125745 · ClinicalTrials.gov registry record · Phase 2
Oral CXA-10 in Pulmonary Arterial Hypertension
A Phase 2 study, sponsored by Gladwin, Mark, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04125745: Clinical Trial Phase 2 study, sponsored by Gladwin, Mark, MD.
NCT04125745 is a Phase 2 study that was terminated before completion, run by Gladwin, Mark, MD. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04125745, a Phase 2 study, was terminated before completion, sponsored by Gladwin, Mark, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the safety and tolerability of 12-week oral CXA-10 therapy in subjects with pulmonary arterial hypertension, with additional evaluation on the clinical efficacy of oral CXA-10 on changes in hemodynamics, exercise capacity, cardiovascular function and patient reported outcomes.
Primary Outcome
Numbers of treatment-related adverse events is assessed by CTCAE v4.0
Interventions
- DRUG CXA-10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-10-31 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 2 |
Why NCT04125745 stopped before completion
NCT04125745 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which CXA-10 is the first listed.
NCT04125745 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04125745 about?
NCT04125745 is a clinical study titled "Oral CXA-10 in Pulmonary Arterial Hypertension". The main objective of this study is to evaluate the safety and tolerability of 12-week oral CXA-10 therapy in subjects with pulmonary arterial hypertension, with additional evaluation on the clinical efficacy of oral CXA-10 on changes in hemodynamics, exercise capacity, cardiovascular function and p...
What is the current status of trial NCT04125745?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2019-10-31. Estimated completion is 2020-12-01.
What interventions are being tested in trial NCT04125745?
The interventions under investigation include: CXA-10 (DRUG).
Who is sponsoring clinical trial NCT04125745?
This trial is sponsored by Gladwin, Mark, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04125745's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI